Stabilisation and determination of the biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) nanospheres

被引:70
作者
Wolf, M
Wirth, M
Pittner, F
Gabor, F
机构
[1] Pharma Ctr Vienna, Inst Pharmaceut Technol & Biopharmaceut, A-1090 Vienna, Austria
[2] Univ Vienna, Inst Biochem & Mol Cell Biol, A-1030 Vienna, Austria
[3] Univ Vienna, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria
关键词
L-asparaginase; lyoprotectant; nanospheres; PLGA; stabilisation; surfactant;
D O I
10.1016/S0378-5173(03)00071-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The preservation of biological activity of protein drugs in formulations is still a major challenge for successful drug delivery. The enzyme L-asparaginase, which exhibits a short in vivo half-life and is only active against leukaemia in its tetrameric form, was encapsulated in poly(D,L-lactide-co-glycolide) nanospheres by the (w/o)/w-emulsion solvent evaporation technique in presence of various potential stabilisers. Elucidation of the preparation steps revealed that the enzyme is denaturated at the aqueous/organic interface and by sonication. The preparation of L-asparaginase nanospheres with trehalose, PEG 400, and glycerol as components of the inner aqueous phase yielded colloidal formulations with increased biological activity as determined by an improved protocol for quantification of the active enzyme encapsulated. After lyophilisation the enzyme activity and particle size distribution were retained only by use of Pluronic F68 as a lyoprotectant. Despite the unaltered particle size and improved biological activity, the release profile of the enzyme was strongly altered by coencapsulation of the stabilisers resulting in increased first bursts. In consequence, the biological activity Of L-asparaginase during preparation and storage can be improved by combining appropriate additives but concurrently the release profile is influenced. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:141 / 152
页数:12
相关论文
共 28 条
[1]  
ALSONSO MJ, 1994, VACCINE, V12, P299
[2]   Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres [J].
Blanco, MD ;
Alonso, MJ .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (03) :287-294
[3]   Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres [J].
Cleland, JL ;
Jones, AJS .
PHARMACEUTICAL RESEARCH, 1996, 13 (10) :1464-1475
[4]   LIPOSOMAL L-ASPARAGINASE - IN-VITRO EVALUATION [J].
CRUZ, MEM ;
GASPAR, MM ;
LOPES, F ;
JORGE, JS ;
PEREZSOLER, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 96 (1-3) :67-77
[5]   Pegylation enhances protein stability during encapsulation in PLGA microspheres [J].
Diwan, M ;
Park, TG .
JOURNAL OF CONTROLLED RELEASE, 2001, 73 (2-3) :233-244
[6]  
ERTL B, 1999, SCI PHARM, V67, P289
[7]   FTIR characterization of the secondary structure of proteins encapsulated within PLGA microspheres' [J].
Fu, K ;
Griebenow, K ;
Hsieh, L ;
Klibanov, AM ;
Langer, R .
JOURNAL OF CONTROLLED RELEASE, 1999, 58 (03) :357-366
[8]  
Gaspar MM, 1998, J CONTROL RELEASE, V52, P53
[9]  
HO DH, 1986, DRUG METAB DISPOS, V14, P349
[10]   Investigation of physicochemical changes L-asparaginase during freeze-thaw cycling [J].
Jameel, F ;
Bogner, R ;
Mauri, F ;
Kalonia, D .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (05) :472-477